Vital Signs - Getting Through to Oncologists: What Cancer Diagnostic Companies Do to Reach Their Key Customer Group
Vital Signs - Getting Through to Oncologists: What Cancer Diagnostic Companies Do to Reach Their Key Customer Group
RELEASE DATE
21-Feb-2011
21-Feb-2011
REGION
North America
North America
Research Code: 9561-00-BD-00-00
SKU: HC00617-NA-MR_04090
$1,500.00
In stock
SKU
HC00617-NA-MR_04090
Description
This issue of Vital Signs, released on February 21, 2011, provides a strategic insight on how cancer diagnostic companies can reach out to their customer base. Additionally, a company spotlight is provided for BioMarker Strategies, a novel tissue-based cancer diagnostics company that is developing the SnapPathTM ex vivo biomarker platform to improve the treatment of cancer. Reimbursement and regulatory news from the FDA is also provided for week of January 31, 2011.
Table of Contents
This week's issue
Popular Topics
This issue of Vital Signs, released on February 21, 2011, provides a strategic insight on how cancer diagnostic companies can reach out to their customer base. Additionally, a company spotlight is provided for BioMarker Strategies, a novel tissue-based cancer diagnostics company that is developing the SnapPathTM ex vivo biomarker platform to improve the treatment of cancer. Reimbursement and regulatory news from the FDA is also provided for week of January 31, 2011.
No Index | Yes |
---|---|
Podcast | No |
Industries | Healthcare |
WIP Number | 9561-00-BD-00-00 |
Is Prebook | No |